Your session is about to expire
← Back to Search
Tumor-Treating Fields + Immunotherapy for Uveal Melanoma
Study Summary
This trial suggests that Tumor Treating Fields may improve outcomes for patients with metastatic uveal melanoma treated with immune checkpoint inhibitors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Is there an age restriction for participation in the clinical trial?
"This medical study is open to participants aged 18-100. Additionally, they have opened 108 clinical trials specifically for those under the age of consent and 1491 such studies are available to patients over 65 years old."
What indications does Opdivo typically address?
"Opdivo is widely used to treat the effects of angiogenesis and can also be utilised in cases with malignant neoplasms, advanced melanomas, and squamous cell carcinoma."
Are there any opportunities to join this experiment at the present time?
"Affirmative. Clinicaltrials.gov information indicates that this trial is actively enrolling participants, with the initial posting appearing on February 28th 2022 and most recent updates occurring March 21st of the same year. The study needs 10 patients from a single location to move forward."
Can you please elucidate on earlier studies that have utilized Opdivo in their research?
"Presently, 764 studies are actively researching the efficacy of Opdivo. Of those trials, 86 are in their final phase. Most tests for this treatment occur at Pittsburgh-based locations; nonetheless, there are 42760 sites hosting clinical trials worldwide."
How many individuals have volunteered to contribute data in this experiment?
"Affirmative, clinicaltrials.gov's records demonstrate that recruitment is still in progress for this medical trial which was initially posted on February 28th 2022 and recently modified on March 21st 2022. The study requires 10 volunteers to be enrolled from a single site."
What evidence is available to demonstrate the security of Opdivo for human use?
"As this is still a Phase 1 study, our team at Power believes that the safety of Opdivo ranks as a 1 out of 3 due to there being limited data backing its efficacy and safety."
Is my eligibility for the experiment under consideration?
"This clinical study is recruiting 10 adults (18 years or older) suffering from metastatic uveal melanoma, mainly in the liver. To be eligible for participation, applicants must meet a series of criteria such as being able to provide informed consent, having normal organ and marrow functions, ECOG 0-1 score and have a minimum life expectancy of 3 months. Moreover, women of childbearing potential need to perform a negative pregnancy test 72 hours prior to their first administration of the drug and both patient and partner must agree on utilizing an reliable form of contraception if actively sexually involved."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger